Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ITUS Presentation to Special Meeting of Stockholders

JPPYY

PR Newswire

SAN JOSE, Calif., April 2, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website.  It can be viewed at http://ir.ituscorp.com/corporate-presentation.

ITUS Logo (PRNewsfoto/ITUS Corporation)

Highlights of the presentation include:

  • Summary of our early cancer detection technology data
  • Results of the blinded prostate cancer study performed with Serametrix Corporation and Memorial Sloane Kettering Cancer Center, showing 92% sensitivity and specificity
  • Summary of our ovarian cancer CAR-T program

Dr. Kumar stated, "With the continued positive advancements of both our diagnostic and therapeutic cancer programs, we are very excited about the company's future and the opportunities to better diagnose and treat cancer in collaboration with academic and corporate partners."

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.  Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/itus-presentation-to-special-meeting-of-stockholders-300622289.html

SOURCE ITUS Corporation



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today